Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis-Reference-Cited by-同舟云学术

Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis

Published:2020-03-23 Issue:2 Volume:34 Page:235-244
ISSN:1173-8804
Container-title:BioDrugs
language:en
Short-container-title:BioDrugs

Author:

Lee Arnold,Scott Lesley J.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine,Biotechnology

Link

http://link.springer.com/content/pdf/10.1007/s40259-020-00416-z.pdf

Reference49 articles.

1. Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645–53.

2. Boehncke W-H, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–94.

3. UCB Inc. Certolizumab pegol (Cimzia): US prescribing information. 2019. http://www.cimzia.com . Accessed 14 Feb 2020.

4. European Medicines Agency. Certolizumab pegol (Cimzia): EU summary of product characteristics. 2019. http://www.ema.europa.eu . Accessed 21 Aug 2019.

5. Dhillon S. Certolizumab pegol: a review of its use in patients with axial spondyloarthritis or psoriatic arthritis. Drugs. 2014;74(9):999–1016.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Approaches and Applications of Nanotechnology in the Delivery of Topical Drugs for Psoriasis via Nanocarriers;Current Nanoscience;2024-08-23

2. Varianten biotechnologischer Arzneistoffe in der Dermatologie;Die Dermatologie;2024-08-22

3. Targeting TNF-α: The therapeutic potential of certolizumab pegol in the early period of cerebral ischemia reperfusion injury in mice;International Immunopharmacology;2024-08

4. An Overview of Contemporary and Future Therapeutic Strategies for Scalp Psoriasis;Current Drug Targets;2024-04

5. Psoriasis and Related Disorders;Rook's Textbook of Dermatology;2024-03-19